The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4- trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons

Journal of Neurochemistry

Volumn 109, Issue 5, 2009, Pages 1261-1271

  Noh, Jihyun ^a   Lee, Eun Sung ^a   Chung, Jun Mo ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Aspirin; Calcium; Electrophysiology; Glutamate; Stroke

Indexed keywords

2 HYDROXY 5 (2,3,5,6 TETRAFLUORO 4 TRIFLUOROMETHYL BENZYLAMINO) BENZOIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DESENSITIZATION; DRUG INHIBITION; ELECTROPHYSIOLOGY; MEMBRANE POTENTIAL; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL;

ANIMALS; BENZOIC ACIDS; BIOPHYSICS; CALCIUM; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; EMBRYO, MAMMALIAN; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; ION CHANNEL GATING; MEMBRANE POTENTIALS; MICE; MICE, INBRED ICR; N-METHYLASPARTATE; NEURONS; PATCH-CLAMP TECHNIQUES; PROTEIN BINDING; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 65549106472     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06044.x     Document Type: Article

References (41)

1. Auberson Y. P., Allgeier H., Bischoff S., Lingenhoehl K., Moretti R. Schmutz M. (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg. Med. Chem. Lett. 12, 1099 1102. (Pubitemid 34242811)
2. Barneoud P. Curet O. (1999) Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. 155, 243 251. (Pubitemid 29124717)
3. Blanchet P. J., Metman L. V. Chase T. N. (2003) Renaissance of amantadine in the treatment of Parkinson's disease. Adv. Neurol. 91, 251 257.
4. Blanpied T. A., Clarke R. J. Johnson J. W. (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 25, 3312 3322. (Pubitemid 40471340)
5. Chen H. S., Pellegrini J. W., Aggarwal S. K., Lei S. Z., Warach S., Jensen F. E. Lipton S. A. (1992) Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12, 4427 4436.
6. Chizh B. A. Headley P. M. (2005) NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr. Pharm. Des. 11, 2977 2994. (Pubitemid 41158087)
7. Dingledine R., Borges K., Bowie D. Traynelis S. F. (1999) The glutamate receptor ion channels. Pharmacol. Rev. 51, 7 61. (Pubitemid 29113865)
8. i. Exp. Neurol. 133, 153 163.
9. Gilling K. E., Jatzke C. Parsons C. G. (2007) Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine. Neuropharmacology 53, 415 420. (Pubitemid 47212248)
10. Gwag B. J., Lee Y. A., Ko S. Y. et al. (2007) Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J. Cereb. Blood Flow Metab. 27, 1142 1151. (Pubitemid 46808702)
11. Hardingham G. E., Fukunaga Y. Bading H. (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 389 390. (Pubitemid 34454245)
12. Harris A. Z. Pettit D. L. (2007) Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J. Physiol. 584, 509 519. (Pubitemid 47578335)
13. Hille B. (2001) Ion Channels of Excitable Membranes, pp. 505 506. Sinauer, Sunderland.
14. Ikonomidou C. Turski L. (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1, 383 386. (Pubitemid 37159164)
15. Kemp J. A. McKernan R. M. (2002) NMDA receptor pathways as drug targets. Nat. Neurosci. 5 (Suppl 1039 1042. (Pubitemid 35247194)
16. Kew J. N., Trube G. Kemp J. A. (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J. Physiol. 497, 761 772. (Pubitemid 27032913)
17. Krupp J. J., Vissel B., Heinemann S. F. Westbrook G. L. (1996) Calcium-dependent inactivation of recombinant N-methyl-d-aspartate receptors is NR2 subunit specific. Mol. Pharmacol. 50, 1680 1688. (Pubitemid 26425127)
18. Legendre P. Westbrook G. L. (1991) Ifenprodil blocks N-methyl-d-aspartate receptors by a two-component mechanism. Mol. Pharmacol. 40, 289 298. (Pubitemid 21907853)
19. Legendre P., Rosenmund C. Westbrook G. L. (1993) Inactivation of NMDA channels in cultured hippocampal neurons by intracellular calcium. J. Neurosci. 13, 674 684. (Pubitemid 23045150)
20. Li B., Chen N., Luo T., Otsu Y., Murphy T. H. Raymond L. A. (2002) Differential regulation of synaptic and extra-synaptic NMDA receptors. Nat. Neurosci. 5, 833 834.
21. Lipton S. A. (2004) Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers. Dis. 6 (Suppl 6 S61 S74. (Pubitemid 40202544)
22. Liu X. B., Murray K. D. Jones E. G. (2004) Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J. Neurosci. 24, 8885 8895. (Pubitemid 39362984)
23. Liu Y., Wong T. P., Aarts M. et al. (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27, 2846 2857. (Pubitemid 46438991)
24. Martel M. A., Wyllie D. J. Hardingham G. E. (2009) In developing hippocampal neurons, NR2B-containing N-methyl-d-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 158, 334 343.
25. Mayer M. L., Vyklicky Jr L. Clements J. (1989) Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature 338, 425 427. (Pubitemid 19089323)
26. Merchant R. E., Bullock M. R., Carmack C. A., Shah A. K., Wilner K. D., Ko G. Williams S. A. (1999) A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. N Y Acad. Sci. 890, 42 50. (Pubitemid 30040363)
27. Miwa H., Fukaya M., Watabe A. M., Watanabe M. Manabe T. (2008) Functional contributions of synaptically localized NR2B subunits of the NMDA receptor to synaptic transmission and long-term potentiation in the adult mouse CNS. J. Physiol. 586, 2539 2550.
28. Mizuta I., Katayama M., Watanabe M., Mishina M. Ishii K. (1998) Developmental expression of NMDA receptor subunits and the emergence of glutamate neurotoxicity in primary cultures of murine cerebral cortical neurons. Cell. Mol. Life Sci. 54, 721 725. (Pubitemid 28379674)
29. Muir K. W. (2006) Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 6, 53 60. (Pubitemid 43103819)
30. Noh J. H., Gwag B. J. Chung J. M. (2006) Underlying mechanism for NMDA receptor antagonism by the anti-inflammatory drug, sulfasalazine, in mouse cortical neurons. Neuropharmacology 50, 1 15. (Pubitemid 43069767)
31. Orser B. A., Pennefather P. S. MacDonald J. F. (1997) Multiple mechanisms of ketamine blockade of N-methyl-d-aspartate receptors. Anesthesiology 86, 903 917. (Pubitemid 27174731)
32. Parsons C. G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S. Danysz W. (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitve NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34, 1239 1258.
33. Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C. Brandt J. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51 55.
34. Robinson D. M. Keating G. M. (2006) Memantine: a review of its use in Alzheimer's disease. Drugs 66, 1515 1534. (Pubitemid 44250755)
35. Rothman S. M. Olney J. W. (1986) Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19, 105 111. (Pubitemid 16114163)
36. Ryu B. R., Lee Y. A., Won S. J. et al. (2003) The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors. J. Pharmacol. Exp. Ther. 305, 48 56. (Pubitemid 36373835)
37. Sather W., Johnson J. W., Henderson G. Ascher P. (1990) Glycine-insensitive desensitization of NMDA responses in cultured mouse embryonic neurons. Neuron 4, 725 731. (Pubitemid 20185087)
38. Sobolevsky A. I., Koshelev S. G. Khodorov B. I. (1999) Probing of NMDA channels with fast blockers. J. Neurosci. 19, 10611 10626. (Pubitemid 30235708)
39. Thomas C. G., Miller A. J. Westbrook G. L. (2006) Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J. Neurophysiol. 95, 1727 1734.
40. Tong G. Jahr C. E. (1994) Regulation of glycine-insensitive desensitization of the NMDA receptor in outside-out patches. J. Neurophysiol. 72, 754 761. (Pubitemid 24273580)
41. Williams K. (1993) Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44, 851 859. (Pubitemid 23317299)